Watchmaker applies advanced enzymology to enable breakthrough applications for the reading, writing, and editing of DNA and RNA. We combine deep domain expertise in protein engineering with largescale enzyme manufacturing to address the demanding quality, performance, and scale requirements of clinical genomics applications.
Watchmaker Genomics
Watchmaker applies advanced enzymology to enable breakthrough applications for the reading, writing, and editing of DNA and RNA. We combine deep domain expertise in protein engineering with largescale enzyme manufacturing to address the demanding quality, performance, and scale requirements of clinical genomics applications.
Wasatch BioLabs
Wasatch BioLabs (WBL) is an independent biotechnology company with a disruptive approach to research and diagnostics. We are an R&D and Oxford Nanopore Technologies-certified laboratory that offers DNA and RNA sequencing services to researchers and clinical service providers. WBL’s solutions span both standard Oxford Nanopore Technologies sequencing services as well as proprietary methylation sequencing services built off of WBL’s NESSI-Seq platform, that expand the capabilities of the nanopore platform. | Wasatch BioLabs, a leading NGS sequencing service provider, harnesses advanced native-read sequencing and streamlined R&D workflows—translating breakthrough discovery into real-world outcomes.
Ultima Genomics
At Ultima Genomics, our mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. The UG 100™ sequencer replaces complex and expensive flow cells with a 200mm open wafer to unlock multiple improvements that reduce cost, increase performance, and provide a roadmap for scalability. Automated wafer handling enables 24/7 continuous operation for flexible, high throughput labs. Our ppmSeq™ technology delivers Q60 SNV accuracy useful for liquid biopsy, MRD, somatic mosaicism, and other emerging applications on the UG 100™. | At Ultima Genomics, our mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. To achieve this, we built a revolutionary new sequencing architecture that scales far beyond conventional technologies, enabling scientists to overcome the tradeoffs they face between the breadth, depth, and frequency of sequencing.
TruDiagnostic
TruDiagnostic Most biomarkers tell you where a patient is right now. DNA methylation tells you where they’re headed and why. TruDiagnostic is a CLIA-certified epigenetics lab and research partner specializing in DNA methylation analysis for biological age, disease risk, and multi-system health performance. Founded in 2020, we’ve built one of the largest private methylation datasets in the world: 200,000+ participants, 80+ published studies, and 115+ active research collaborators – including institutions publishing in Nature Aging and peer-reviewed clinical journals. Our positioning is deliberate: science over commercialization. Every product we offer is grounded in rigorous, independently validated research. What we bring to the table for our partners: Our Epigenetic Biomarker Proxies (EBPs) predict 2,000+ protein and metabolite biomarkers directly from a blood spot. In head-to-head comparisons, these DNA Methylation derived biomarkers outperform traditional direct measurements 62% of the time, with better effect sizes and greater signal stability. Unlike point-in-time assays, methylation patterns reflect long-term biological averages, making them less susceptible to day-to-day biological noise. Our Methylation Risk Scores (MRS) predict 5- and 10-year disease risk with ~90% accuracy across cardiovascular disease, diabetes, Alzheimer’s, Parkinson’s, and cognitive decline. Unlike polygenic risk scores, MRS are modifiable — they respond to interventions, making them uniquely actionable for clinical trials, therapeutic validation, and personalized medicine applications. Our immune deconvolution platform reconstructs cell-type composition from whole blood with only a 3% error rate compared to flow cytometry, at a fraction of the cost and complexity. We collaborate across pharma, consumer health, and clinical research. Deliverables include processed IDAT files and beta values, custom aging clocks, organ-specific risk scores, cohort-level analysis reports, and intervention efficacy assessments. Our work with Olaplex on tissue-specific skin aging demonstrates how this technology extends well beyond blood. If you’re running clinical trials, building risk stratification tools, or looking for a methylation data partner with the depth to support real discovery, we’re built for that conversation.
Tasso, Inc.
Tasso is a healthcare technology company transforming traditional blood collection with a patient-centric, virtually painless approach. Its devices enable simple, remote blood sampling for users and healthcare providers. Headquartered in Seattle, Washington, Tasso is privately held and supported through grants, investments, and partnerships with leading research and industry organizations. Learn more at www.tassoinc.com.
SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally.
SeqOne
SeqOne is a leading European provider of AI-powered software for next-generation sequencing (NGS) data analysis in oncology and rare diseases. Its cloud-based platform transforms complex genomic data into fast, precise, and actionable insights, supporting molecular labs in delivering life-saving diagnoses and treatments. The SeqOne Platform is CE-IVD Class C certified under HIPAA as an in vitro diagnostic medical device. Driven by the vision of personalized medicine for every patient, everywhere, SeqOne is scaling the future of genomic medicine—one lab at a time. The company has won numerous awards, including the iLab award and the ARC Cancer Foundation’s Hélène Stark prize. It has been nominated twice for the prestigious Prix Galien award. Investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes, and Software Club. | SeqOne is a leading European provider of AI-powered software for next-generation sequencing (NGS) data analysis in oncology and rare diseases. Its cloud-based platform transforms complex genomic data into fast, precise, and actionable insights, supporting molecular labs in delivering life-saving diagnoses and treatments. The SeqOne Platform is CE-IVD Class C certified under IVDR as an in vitro diagnostic medical device. Driven by the vision of personalized medicine for every patient, everywhere, SeqOne is scaling the future of genomic medicine—one lab at a time. The company has won numerous awards, including the iLab award and the ARC Cancer Foundation’s Hélène Stark prize. It has been nominated twice for the prestigious Prix Galien award. Investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes, and Software Club.
SeqCenter
SeqCenter is a sequencing service provider located in Pittsburgh, PA. We offer services on Illumina, PacBio, and Oxford Nanopore platforms. We are excited to launch our Illumina Protein Prep services at ASHG.